The aldosterone antagonist and facultative diuretic eplerenone: A critical review

European Journal of Internal Medicine

Volumn 16, Issue 1, 2005, Pages 3-11

  Reyes, Ariel J ^a   Leary, William P ^b   Crippa, Giuseppe ^c   Maranhão, Mário F C ^d   Hernández Hernández, Rafael ^e  

^a Institute of Cardiovascular Theory Montevideo   (Uruguay)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c Guglielmo Da Salicileto Hospital   (Italy)

^d Evangelical Medical School   (Brazil)

^e UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

Heart failure; Hepatic edema; Hyperaldosteronism; Hyperkalemia; Hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; BENDROFLUMETHIAZIDE; CANRENOATE POTASSIUM; CHLORTALIDONE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ERYTHROMYCIN; FLUCONAZOLE; HYDROCHLOROTHIAZIDE; LISINOPRIL; SAQUINAVIR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG INDICATION; EDEMA; GYNECOMASTIA; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; IMPOTENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER EDEMA; MASTALGIA; METABOLIC ACIDOSIS; NATRIURESIS; NONHUMAN; PARALYSIS; REVIEW; SODIUM INTAKE; VAGINA BLEEDING;

EID: 14144255193     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2004.10.007     Document Type: Review

References (134)

1. A.J. Zillich, and B.L. Carter Eplerenone-a novel selective aldosterone blocker Ann. Pharmacother. 36 2002 1567 1576
2. H. Krum, H. Nolly, D. Workman, W. He, B. Roniker, and S. Krause Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients Hypertension 40 2002 117 123
3. M.H. Weinberger, B. Roniker, S.L. Krause, and R.J. Weiss Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am. J. Hypertens. 15 2002 709 716
4. W.P. Leary, A.J. Reyes, and K. van der Byl The antialdosterone substance spironolactone is a facultative natriuretic, antikaliuretic and antimagnesiuretic in man J.B. Puschett A. Greenberg Diuretics IV: chemistry, pharmacology and clinical applications 1993 Excerpta Medica Amsterdam 391 394
5. W.P. Leary, A.J. Reyes, and K. van der Byl Spironolactone is a facultative diuretic and antimagnesiuretic in man S. Golf D. Dralle L. Vecchiet Magnesium 1993 1994 John Libbey London 299 302
6. P.O. Lim, W.F. Young, and T.M. MacDonald A review of the medical treatment of primary aldosteronism J. Hypertens. 19 2001 353 361
7. W.F. Young Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment Endocrinology 144 2003 2208 2213
8. S. Nadar, G.Y. Lip, and D.G. Beevers Primary hyperaldosteronism Ann. Clin. Biochem. 40 2003 439 452
9. M. Stowasser, R.D. Gordon, T.G. Gunasekera, D.C. Cowley, G. Ward, and C. Archibald High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients J. Hypertens. 21 2003 2149 2157
10. D.A. Calhoun, M.K. Nishizaka, M.A. Zaman, R.P. Thakkar, and P. Weissmann Hyperaldosteronism between Black and White subjects with resistant hypertension J. Hypertens. 40 2002 892 896
11. J. Ouzan, C. Perault, A.M. Lincoff, E. Carre, and M. Mertes The role of spironolactone in the treatment of patients with refractory hypertension Am. J. Hypertens. 15 2002 333 339
12. P.O. Lim, R.T. Jung, and T.M. MacDonald Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity J. Hum. Hypertens. 16 2002 153 158
13. P.O. Lim, R.T. Jung, and T.M. MacDonald Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study Br. J. Clin. Pharmacol. 48 1999 756 760
14. B.L. Rayner, L.H. Opie, and J.S. Davidson The aldosterone/renin ratio as a screening test for primary aldosteronism S. Afr. Med. J. 90 2000 394 400
15. C.A. Brown, M.J. Bouldin, J.W. Blackston, D.N. Duddleston, J.M. Shepherd, and G.S. Hicks Hyperaldosteronism: the internist's hypertensive disease Am. J. Med. Sci. 324 2002 227 231
16. R.J. Auchus Aldo is back: recent advances and unresolved controversies in hyperaldosteronism Curr. Opin. Nephrol. Hypertens. 12 2003 153 158
17. W.F. Young Primary aldosteronism-treatment options Growth Horm. IGF Res. 13 Suppl. A 2003 S102 S108
18. B.J. Materson Reassessing the role of spironolactone in hypertension Adv. Ther. 3 1986 381 405
19. A.N. Brest Spironolactone in the treatment of hypertension: a review Clin. Ther. 8 1986 568 585
20. X. Jeunemaitre, G. Chatellier, C. Kreft-Jais, A. Charru, C. DeVries, and P.F. Plouin Efficacy and tolerance of spironolactone in essential hypertension Am. J. Cardiol. 60 1987 820 825
21. M. Weinberger, T. MacDonald, P.R. Conlin, B. Ronicker, J.L. Patrick, and S. Krause Comparison of eplerenone and losartan in patients with low-renin hypertension Am. J. Hypertens. 15 2002 24A
22. N. Epstein, W. Buckalew Jr., F. Martinez, J. Altamirano, B. Ronicker, and J. Kleiman Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria Am. J. Hypertens. 15 2002 24A
23. J.M. Flack, S. Oparil, J.H. Pratt, B. Ronicker, S. Garthwaite, and J.H. Kleiman Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients J. Am. Coll. Cardiol. 41 2003 1148 1155
24. W.B. White, D. Duprez, R. St. Hillaire, S. Krause, B. Roniker, and J. Kuse-Hamilton Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension Hypertension 92 2003 38 42
25. B. Pitt, N. Reichek, R. Willenbrock, F. Zannad, R.A. Phillips, and B. Roniker Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study Circulation 108 2003 1831 1838
26. N.K. Hollenberg, G.H. Williams, R. Anderson, K.S. Akhras, R.M. Bittman, and S.L. Krause Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension Arch. Intern. Med. 163 2003 1543 1548
27. E.D. Burgess, Y. Lacourciere, L.M. Ruilope-Urioste, S. Oparil, J.H. Kleiman, and S. Krause Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension Clin. Ther. 25 2003 2388 2404
28. Inspra (eplerenone USA approved prescribing information, October 2003) [11 screens]. Available from URL: http://www.pfizer.com/download/uspi_inspra. pdf. Accessed on the 26 October, 2003.
29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
30. B.M. Psaty, N.L. Smith, D.S. Siscovick, T.D. Koepsell, N.S. Weiss, and S.R. Heckbert Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis JAMA 277 1997 739 745
31. M.D. Fotherby, and J.F. Potter Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives J. Hum. Hypertens. 11 1997 361 366
32. D.A. Calhoun, M.A. Zaman, and M.K. Nishizaka Resistant hypertension Curr. Hypertens. Rep. 4 2002 221 228
33. M.K. Nishizaka, M.A. Zaman, and D.A. Calhoun Efficacy of low-dose spironolactone in subjects with resistant hypertension Am. J. Hypertens. 16 2003 925 930
34. Scholze J for the East Germany Collaborative Trial Group A. Breitstadt, V. Cairns, B. Bauer, N. Bender, and C. Priestley Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design J. Hypertens. 11 Suppl. 2 1993 S25 S33
35. J.H. MacKay, K.E. Arcuri, Al. Goldberg, S.M. Snapinn, and C.S. Sweet Losartan and low-dose hydrochlorothiazide in patients with essential hypertension Arch. Intern. Med. 156 1996 278 285
36. Y. Korduner, l. Käbin, and G. Hagbarth Low-dose chlorthalidone treatment in previously untreated hypertension Curr. Ther. Res. Clin. Exp. 29 1981 208 215
37. G. Pollavini, D. Comi, C. Grillo, M. Lombardo, O. Mantero, and L. Minetti Multicentre randomized cross-over double-blind comparison between chlorthalidone and slow-release oxprenolol in mild-to-moderate hypertension Curr. Ther. Res. Clin. Exp. 35 1984 465 475
38. J.E. Carlsen, L. Kober, C. Torp-Pedersen, and P. Johansen Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects BMJ 300 1990 975 978
39. B. Girvin, and G.D. Johnston A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients J. Hypertens. 16 1998 1049 1054
40. A.J. Reyes Diuretics in the therapy of hypertension J. Hum. Hypertens. 16 Suppl. 1 2002 S78 S83
41. C.J. Roberts, A.J. Marshall, S. Heaton, and D.W. Barritt Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone Br. Med. J. 1 1979 224 226
42. X. Jeunemaitre, A. Charru, G. Chatellier, P. Degoulet, J. Julien, and P.F. Plouin Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension Am. J. Cardiol. 62 1988 1072 1077
43. L.V. Franse, M. Pahor, M. Di Bari, G.W. Somes, W.C. Cushman, and W.B. Applegate Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program Hypertension 35 2000 1025 1030
44. D.S. Siscovick, T.E. Raghunathan, B.M. Psaty, T.D. Koepsell, K.G. Wicklund, and X. Lin Diuretic therapy for hypertension and the risk of primary cardiac arrest N. Engl. J. Med. 330 1994 1852 1857
45. D.E. Grobbee, and A.W. Hoes Non-potassium-sparing diuretics and risk of sudden cardiac death J. Hypertens. 13 1995 1539 1545
46. S.H. Slight, J. Joseph, V.K. Ganjam, and K.T. Weber Extra-adrenal mineralocorticoids and cardiovascular tissue J. Mol. Cell. Cardiol. 3 1999 1175 1184
47. C.G. Brilla Aldosterone and myocardial fibrosis in heart failure Herz 25 2000 299 306
48. P. Lijnen, and V. Petrov Induction of cardiac fibrosis by aldosterone J. Mol. Cell. Cardiol. 32 2000 865 879
49. M.J. Young, and J.W. Funder Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system J. Hypertens. 20 2002 1465 1468
50. A. Virdis, M.F. Neves, F. Amiri, E. Viel, M.R. Touyz, and E.L. Schiffrin Spironolactone improves angiotensin-induced vascular changes and oxidative stress Hypertension 40 2002 504 510
51. J.G. Mill, C. Milanez, M.M. Resende, G. Gomes, and C.M. Leite Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats Clin. Exp. Pharmacol. Physiol. 30 2003 739 744
52. P. Lacolley, C. Labat, A. Pujol, C. Delcayre, A. Benetos, and M. Safar Increased carotid wall elastic modulus and fibronectin in aldosterone-salt- treated rats: effects of eplerenone Circulation 106 2002 2848 2853
53. D.V. Martinez, R. Rocha, M. Matsumura, E. Oestreicher, M. Ochoa-Maya, and W. Roubsanthisuk Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading Hypertension 39 2002 614 618
54. R. Rocha, and J.W. Funder The pathophysiology of aldosterone in the cardiovascular system Ann. N.Y. Acad. Sci. 970 2002 89 100
55. S. Hein, E. Arnon, S. Kostin, M. Schonburg, A. Elsasser, and V. Polyakova Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms Circulation 107 2003 984 991
56. A.M. Grandi, D. Imperiale, R. Santillo, E. Barlocco, A. Bertolini, and L. Guasti Aldosterone antagonist improves diastolic function in essential hypertension Hypertension 40 2002 647 652
57. B.J. Materson Diuretic therapy of hypertension in the United States: low-dose becomes lower Prog. Pharmacol. Clin. Pharmacol. 10/3 1995 33 45
58. A.D. Struthers Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure J. Card. Fail. 2 1996 47 54
59. J. Lakkis, W.X. Lu, and M.R. Weir RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease Curr. Hypertens. Rep. 5 2003 408 417
60. U.P. Jorde, T. Vittorio, S.D. Katz, P.C. Colombo, F. Latif, and T.H. Le Jemtel Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure Circulation 106 2002 1055 1057
61. A.J. Reyes Diuretics in the treatment of patients who present congestive heart failure and hypertension J. Hum. Hypertens. 16 Suppl. 1 2002 S104 S113
62. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez The effect of spironolactone on morbidity and mortality in patients with severe heart failure N. Engl. J. Med. 341 1999 709 717
63. M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, and G. Brighetti Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure J. Am. Coll. Cardiol. 40 2002 304 310
64. M.F. Rousseau, O. Gurne, D. Duprez, W. Van Mieghem, A. Robert, and S. Ahn Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy J. Am. Coll. Cardiol. 40 2002 1596 1601
65. M. Domanski, J. Norman, B. Pitt, M. Haigney, S. Hanlon, and E. Peyster Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD) J. Am. Coll. Cardiol. 42 2003 705 708
66. F. Zannad, B. Dousset, and F. Alla Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship Hypertension 38 2001 1227 1232
67. R. Rocha, C.L. Martin-Berger, P. Yang, R. Scherrer, J. Delyani, and E. McMahon Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart Endocrinology 143 2002 4828 4836
68. R. Rocha, A.E. Rudolph, G.E. Frierdich, D.A. Nachowiak, B.K. Kekec, and E.A. Blomme Aldosterone induces a vascular inflammatory phenotype in the rat heart Am. J. Physiol., Heart Circ. Physiol. 283 2002 H1802 H1810
69. S. Neumann, K. Huse, R. Semrau, A. Diegeler, R. Gebhardt, and G.H. Buniatian Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vivo Hypertension 39 2002 756 760
70. M. Hayashi, T. Tsutamoto, A. Wada, T. Tsutsui, C. Ishii, and K. Ohno Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565
71. T.Y. Chun, L.J. Bloem, and J.H. Pratt Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes Endocrinology 144 2003 1712 1717
72. A. Cittadini, M.G. Monti, J. Isgaard, C. Casaburi, H. Stromer, and A. Di Gianni Aldosterone-receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure Cardiovasc. Res. 58 2003 555 564
73. A. Lal, J.P. Veinot, and F.H. Leenen Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone Am. J. Hypertens. 16 2003 319 323
74. W. Qin, A.E. Rudolph, B.R. Bond, R. Rocha, E.A. Blomme, and J.J. Goellner Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure Circ. Res. 93 2003 69 76
75. D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone-receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J. Am. Coll. Cardiol. 42 2003 1666 1673
76. A. Schafer, D. Fraccarollo, S. Hildemann, M. Christ, M. Eigenthaler, and A. Kobsar Inhibition of platelet activation in congestive heart failure by aldosterone-receptor antagonism and ACE inhibition Thromb. Haemost. 89 2003 1024 1030
77. A. Schafer, D. Fraccarollo, S.K. Hildemann, P. Tas, G. Ertl, and J. Bauersachs Addition of the selective aldosterone-receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction Cardiovasc. Res. 58 2003 655 662
78. S. Keidar, T. Hayek, M. Kaplan, E. Pavlotzky, S. Hamoud, and R. Coleman Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein e-deficient mice J. Cardiovasc. Pharmacol. 41 2003 955 963
79. S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, and T. Suzuki Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy J. Am. Coll. Cardiol. 41 2003 574 581
80. C. Delcayre, and B. Swynghedauw Molecular mechanisms of myocardial remodeling. The role of aldosterone J. Mol. Cell. Cardiol. 34 2002 1577 1584
81. P.J. Lijnen, and V.V. Petrov Role of intracardiac renin-angiotensin- aldosterone system in extracellular matrix remodeling Methods Find. Exp. Clin. Pharmacol. 25 2003 541 564
82. M.J. Young, C.D. Clyne, T.J. Cole, and J.W. Funder Cardiac steroidogenesis in the normal and failing heart J. Clin. Endocrinol. Metab. 86 2001 5121 5126
83. E. Davies, and S.M. MacKenzie Extra-adrenal production of corticosteroids Clin. Exp. Pharmacol. Physiol. 30 2003 437 445
84. T. Tsutamoto, A. Wada, K. Maeda, M. Hayashi, T. Tsutsui, and M. Ohnishi Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure J. Cardiovasc. Pharmacol. 41 Suppl. 1 2003 S19 S22
85. B. Pitt, W.J. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
86. V. Arroyo, and P. Gines Therapy with diuretics in hepatic disease with edema and management of refractory ascites Prog. Pharmacol. Clin. Pharmacol. 9 1992 619 652
87. B.F. Palmer Pathogenesis of ascites and renal salt retention in cirrhosis J. Investig. Med. 47 1999 183 202
88. K.P. Moore, F. Wong, P. Gines, M. Bernardi, A. Ochs, and F. Salerno The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club Hepatology 38 2003 258 266
89. The RALES Investigators Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) Am. J. Cardiol. 78 1996 902 907
90. B. Georges, C. Beguin, and M. Jadoul Spironolactone and congestive heart failure Lancet 355 2000 1369 1370
91. H. Schepkens, R. Vanholder, J.M. Billiouw, and N. Lameire Life-threatening hyperkalemia during combined therapy with angiotensin- converting enzyme inhibitors and spironolactone: an analysis of 25 cases Am. J. Med. 110 2001 438 441
92. Y. Hu, J.P. Carpenter, and A.T. Cheung Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency Anesth. Analg. 95 2002 39 41
93. J.W. Taylor Mental symptoms and electrolyte imbalance Aust. N. Z. J. Psychiatry 13 1979 159 160
94. D.A. Feinfeld, and C.P. Carvounis Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment JAMA 240 1978 1516
95. J.E. O'Connell, and N.R. Colledge Type IV renal tubular acidosis and spironolactone therapy in the elderly Postgrad. Med. J. 69 1993 887 889
96. J.P. Knochel Clinical expression of potassium disturbances D.W. Seldin G. Giebisch The regulation of potassium balance 1989 Raven New York 207 240
97. J.G. Verbalis Hyponatremia Baillière's Clin. Endocrinol. Metab. 3 1989 499 530
98. E.O. Udezue, and B.P. Harrold Hyperkalaemic paralysis due to spironolactone Postgrad. Med. J. 56 1980 254 255
99. J.P. Rado Successful treatment of hyperkalemic quadriplegia associated with spironolactone Int. J. Clin. Pharmacol. Ther. Toxicol. 26 1988 339 345
100. C. Pongpaew, R.N. Songkhla, and R.L. Kozam Hyperkalemic cardiac arrhythmia secondary to spironolactone Chest 63 1973 1023 1025
101. V. Yap, A. Patel, and J. Thomsen Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia JAMA 236 1976 2775 2776
102. H.W. Cohen, S. Madhavan, and M.H. Alderman High and low serum potassium associated with cardiovascular events in diuretic-treated patients J. Hypertens. 19 2001 1315 1323
103. M.G. McGeown Spironolactone and hyperkalaemia in patients with impaired renal failure Lancet 2 1987 1207
104. M.G. Shlipak Pharmacotherapy for heart failure in patients with renal insufficiency Ann. Intern. Med. 138 2003 917 924
105. C.I. Obialo, E.O. Ofili, and T. Mirza Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease Am. J. Cardiol. 90 2002 663 665
106. T.J. Neale, K.L. Lynn, and R.R. Bailey Spironolactone-associated aggravation of renal functional impairment N. Z. Med. J. 83 1976 147 149
107. C. Anton, A.R. Cox, R.D. Watson, and R.E. Ferner The safety of spironolactone treatment in patients with heart failure J. Clin. Pharm. Ther. 28 2003 285 287
108. P.P. Lamy Potential adverse effects of antihypertensive drugs in the elderly J. Hypertens. 6 Suppl. 1 1988 S81 S85
109. M.R. Tuck Clinical care of the aging hypertensive patient J. Cardiovasc. Pharmacol. 12 Suppl. 8 1988 S40 S48
110. M.A. Weber, J.M. Neutel, and D.G. Cheung Hypertension in the aged: a pathophysiologic basis for treatment Am. J. Cardiol. 63 1989 25H 32H
111. S.P. Ponce, A.E. Jennings, N.E. Madias, and J.T. Harrington Drug-induced hyperkalemia Medicine 64 1985 357 370
112. R.A. Preston, M.J. Hirsh, J.R. Oster, and H.R. Oster University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia Am. J. Ther. 5 1998 125 132
113. C.J. Doorenbos, and C.G. Vermeij Danger of salt substitutes that contain potassium in patients with renal failure BMJ 326 2003 35 36
114. V.M. Stepan, H.F. Hammer, and G.J. Krejs Hyperkalaemia and diarrhoea in a patient with surreptitious ingestion of potassium sparing diuretics Eur. J. Gastroenterol. Hepatol. 9 1997 1001 1004
115. C. Berry, and J.J. McMurray Serious adverse events experienced by patients with chronic heart failure taking spironolactone Heart 85 2001 E8
116. C.S. Cruz, A.A. Cruz, and C.A. Marcilio De Souza Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone Nephrol. Dial. Transplant. 18 2003 1814 1819
117. E. Wrenger, R. Muller, M. Moesenthin, T. Welte, J.C. Frolich, and K.H. Neumann Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases BMJ 327 2003 147 149
118. A. Henger, P. Tutt, W.F. Riesen, H.N. Hulter, and R. Krapf Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients J. Lab. Clin. Med. 136 2000 379 389
119. D.O. Stichtenoth, and J.C. Frolich COX-2 and the kidneys Curr. Pharm. Des. 6 2000 1737 1753
120. R.C. Harris Jr. Cyclooxygenase-2 inhibition and renal physiology Am. J. Cardiol. 89 6A 2002 10D 17D
121. J.I. Schwartz, K. Vandormael, M.P. Malice, R.N. Kalyani, K.C. Lasseter, and G.B. Holmes Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet Clin. Pharmacol. Ther. 72 2002 50 61
122. B. Bozkurt, I. Agoston, and A.A. Knowlton Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J. Am. Coll. Cardiol. 41 2003 211 214
123. M. Svensson, F. Gustafsson, S. Galatius, P.R. Hildebrandt, and D. Atar Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study BMJ 327 2003 1141 1142
124. M.A. Manuel, O.J. Beirne, J.T. Wagnaild, and M.W. Weiner An effect of spironolactone on urinary acidification in normal man Arch. Intern. Med. 134 1974 472 474
125. H.N. Hulter, E.L. Bonner Jr., R.D. Glynn, and A. Sebastian Renal and systemic acid-base effects of chronic spironolactone administration Am. J. Physiol. 240 1981 F381 F387
126. T.Y. Chan Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management Drugs Aging 11 1997 27 44
127. M. Miller Inappropriate antidiuretic hormone secretion Curr. Ther. Endocrinol. Metab. 6 1997 206 209
128. M.M. Hirschl, D. Seidler, and A.N. Laggner Spironolactone-associated hyponatremic coma Nephron 67 1994 503
129. E. Orinius Hyponatremia in congestive heart failure treated with diuretics Acta Pharm. Toxicol. 54 Suppl. 1 1984 115 118
130. A.J. Reyes, and W.P. Leary Renal excretory responses to single and repeated administration of diuretics in healthy subjects. Clinical connotations Cardiovasc. Drugs Ther. 7 1993 29 44
131. A. Spital Diuretic-induced hyponatremia Am. J. Nephrol. 19 1999 447 452
132. O.S. Ashouri Severe diuretic-induced hyponatremia in the elderly Arch. Intern. Med. 146 1986 1355 1357
133. P. Fernandez, and M. Choi Thiazide-induced hyponatremia J.B. Puschett A. Greenberg Diuretics IV: chemistry, pharmacology and clinical applications 1993 Excerpta Medica Amsterdam 3 11
134. K.T. Weber Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone J. Lab. Clin. Med. 14 2003 71 82